(Natural News)—In a groundbreaking report released this week, a Florida grand jury has uncovered “profound and serious issues” in the U.S. vaccine development and safety surveillance system. While the jury found no criminal activity, it revealed a troubling pattern of “deceptive and obfuscatory behavior” by pharmaceutical companies and regulators, raising urgent questions about transparency, ethics, and accountability in the nation’s public health infrastructure.
The grand jury, convened by Florida Governor Ron DeSantis in December 2022, was tasked with investigating “any and all wrongdoing” related to COVID-19 vaccines. After a year-long review of documents, interviews with key witnesses, and an examination of the vaccine production process, the jury’s 140-page report paints a damning picture of a system rife with conflicts of interest, lack of transparency, and ethical lapses.
“While we did not find criminal activity,” the report states, “we did find a pattern of deceptive and obfuscatory behavior on the part of sponsors and regulators that often straddled the line between ethical and unethical conduct.” The report emphasizes that the absence of criminal charges does not equate to an absence of problems. On the contrary, it highlights systemic flaws that, if left unaddressed, will continue to undermine public trust in vaccines and the institutions tasked with safeguarding public health.
A system in need of reform
The grand jury’s findings reveal a litany of issues plaguing the vaccine development and regulatory process. Among the most alarming revelations is the failure of pharmaceutical giant Pfizer to disclose adverse events in pregnant women during one of its key clinical trials. These events were omitted from published studies in the New England Journal of Medicine and only came to light because Pfizer was legally required to post trial results on ClinicalTrials.gov.
The report also criticizes the FDA for its lax enforcement of marketing restrictions on vaccine companies. For example, Moderna’s 2021 ad campaign, which featured a former athlete urging Americans to “protect the team” by getting vaccinated, was allowed to run despite promoting vaccination in general rather than a specific product. This blurring of lines between public health messaging and corporate advertising raises concerns about the FDA’s role as a regulator versus a cheerleader for the pharmaceutical industry.
Perhaps most troubling is the “revolving door” between the FDA and the pharmaceutical industry, a phenomenon documented in a 2024 investigation by Peter Doshi, Ph.D., senior editor at The BMJ. Doshi’s research revealed that departing FDA staff often take lucrative positions in the pharmaceutical sector, where they continue to influence regulatory decisions “behind the scenes.” This cozy relationship, the grand jury argues, undermines the FDA’s ability to act as an impartial watchdog.
Recommendations for change
The grand jury’s report is not merely a critique; it is a call to action. The jury offers six key recommendations to reform the vaccine development and regulatory process:
- Address the revolving door: The public must confront the pervasive conflicts of interest created by the movement of personnel between government agencies and the pharmaceutical industry.
- Disclose safety signals immediately: Vaccine makers should be required to publicly disclose safety signals as soon as they are identified, rather than waiting for confirmation. The report argues that treating the public as incapable of understanding nuanced information is “infantilizing and paternalistic.”
- Conduct updated clinical trials: Pfizer and Moderna’s COVID-19 vaccines should undergo updated clinical trials to address lingering questions about their safety and efficacy.
- Ban direct-to-consumer marketing: The practice of pharmaceutical companies advertising directly to consumers should be prohibited to prevent the manipulation of public perception.
- Publish anonymized patient data: Vaccine makers must swiftly release anonymized individual patient data from safety and efficacy studies after receiving FDA licensure.
- Remove legal immunity: Companies that fail to comply with data transparency requirements should lose their legal immunity from lawsuits.
A call for systemic change
The grand jury’s report is careful to avoid taking sides in the polarized debate over COVID-19 vaccines. It acknowledges that the vaccines have been hailed as a “triumph of science” by some and criticized as recklessly overpromoted by others. Both perspectives, the report suggests, contain elements of truth.
What the jury seeks is not to fuel ideological battles but to spark a much-needed conversation about systemic reform. “If this Final Report accomplishes nothing else,” the authors write, “we are optimistic that it can elevate the debate around the many nuanced and specific issues involving these pharmaceuticals by clearly describing and contextualizing them.”
Governor DeSantis echoed this sentiment in a statement on X, emphasizing that the status quo is untenable. “The American people deserve transparency on how Big Pharma is using their federal tax dollars,” he said, “and they deserve regulating entities that operate as watchdogs, not cheerleaders.”
A blueprint for the future
The grand jury’s findings and recommendations represent a critical step toward restoring public trust in the vaccine development process. By shining a light on the ethical and systemic issues that have plagued the system, the report provides a blueprint for meaningful reform.
As the nation grapples with the lessons of the COVID-19 pandemic, this report serves as a stark reminder that transparency, accountability, and ethical governance are not optional—they are essential to the health and well-being of the American people. The question now is whether policymakers, regulators, and the pharmaceutical industry will heed this call for change or continue to prioritize profit over public trust.
For those who value natural health and informed consent, the grand jury’s report is a vindication of long-held concerns about the influence of Big Pharma and the need for a more balanced, transparent approach to public health. The time for systemic change is now.
Sources include:
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.